Multilayer Nalbuphine Formulation for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of nalbuphine, a synthetic opioid agonist-antagonist analgesic, have limited duration of action and require frequent dosing, leading to undertreated pain and potential side effects due to peak concentration variability.
Innovation Solution
Development of an oral solid unit dosage form with a sustained release delivery system comprising a hydrophilic compound and a cross-linking agent, which releases 75-100% of nalbuphine within 12 hours, providing controlled release for at least 8 hours, using a multilayer composition with immediate and extended release layers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation is used, then rapid analgesic effect is achieved, but dosing frequency must be increased every 3-6 hours
Solution Approach 1:
The oral dosage form is divided into two distinct layers: an immediate release layer containing nalbuphine HCl for rapid onset, and an extended release layer containing nalbuphine base in a sustained release delivery system for prolonged duration. This segmentation allows each layer to perform its specific function independently, resolving the contradiction between rapid onset and extended duration.
Solution Approach 2:
The multilayer formulation creates a periodic release pattern where the immediate release layer provides initial drug release for rapid effect, followed by the extended release layer that maintains therapeutic levels over 12-24 hours. This periodic action pattern ensures both rapid onset and sustained duration without requiring frequent redosing.
2Reliability
If frequent dosing is administered, then adequate pain control is maintained, but peak concentration variability increases causing side effects
Solution Approach 1:
The extended release layer provides continuous drug release over 12-24 hours, maintaining steady therapeutic concentrations without the peaks and troughs associated with frequent dosing. This continuity ensures reliable pain control while minimizing concentration variability that causes side effects.
3Ease of operation
If oral administration is developed, then patient convenience is improved, but nalbuphine has never received marketing approval for oral route
Solution Approach 1:
The formulation uses a composite multilayer structure combining immediate release and extended release components with different nalbuphine salts (HCl and base) and delivery systems. This composite approach addresses the complex challenges of oral nalbuphine delivery, improving bioavailability and maintaining stability, which are necessary for regulatory approval.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained release formulation reduces dosing frequency, minimizes side effects by lowering peak drug concentrations, and maintains analgesic effect for an extended period, suitable for moderate to severe pain management.
Implementation Method 1
The sustained release delivery system may include (i) at least one hydrophilic compound, at least one cross-linking agent, and at least one pharmaceutical diluent; or (ii) at least one hydrophilic compound, at least one cross-linking agent, at least one pharmaceutical diluent, and at least one cationic cross-linking compound different from the first cross-linking compound.
Implementation Method 2
75-100% of the nalbuphine is released after about 12 hours as determined using USP Apparatus III at 15 dpm in a pH 6.8 buffer at 37°C and providing controlled release for at least 8 hours.
Data Source
Figure 1
AI summary
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.